Harmony Biosciences Holdings, Inc. (HRMY) Cash Flow Statement

The gap between net income and operating cash flow is the central signal here, and it is uneven across the ten quarters shown. Quarters where operating cash flow exceeds net income, such as 2025Q4 at 5.61 times, appear to reflect large working capital releases rather than structurally higher earnings power. Investors should treat the trailing cash conversion as more informative than any single quarter, and should monitor whether receivables and channel inventory reverse those gains.

Because CapEx is near zero across the period, free cash flow tracks operating cash flow almost entirely, so the margin volatility reflects working capital and earnings timing rather than investment intensity. The strong 2025 quarters and the weaker early-2026 quarters suggest the business generates cash in lumps tied to receivable collection. Analysts should avoid annualizing a single strong quarter and should instead weight the trailing average.

This magnitude of working capital movement relative to quarterly operating cash flow suggests collections timing and specialty pharmacy inventory levels are the dominant variables. The pattern is consistent with the channel inventory sensitivity noted in the income statement analysis, though the underlying receivable and inventory balances are not broken out in the data provided. Investors should monitor whether the 2026Q1 outflow reflects normal seasonal rebuilding or a slowdown in collections.

The absence of dividends and the minimal repurchase activity suggest management is prioritizing balance sheet optionality, which is consistent with a single-asset company still funding pipeline development. Acquisition outflows of $33.1M in 2024Q2 and $19.2M in 2025Q4 indicate that retained cash has been partly deployed toward external growth. Whether these deployments generate adequate returns remains unproven in the cash flow data provided.